@article {Combe1063, author = {Bernard Combe and Frank Behrens and Neil McHugh and Fiona Brock and Urs Kerkmann and Blerina Kola and Gaia Gallo}, title = {Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials}, volume = {43}, number = {6}, pages = {1063--1067}, year = {2016}, doi = {10.3899/jrheum.151290}, publisher = {The Journal of Rheumatology}, abstract = {Objective. To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA).Methods. Data from patients with PsA who received ETN alone (n = 322) or combined with methotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies.Results. Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80\% and 83\%) and the American College of Rheumatology improvements of 20\% (ACR20; both 70\%); numerically higher proportions receiving monotherapy achieved ACR50 (55\% vs 48\%) and ACR70 (35\% vs 27\%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire{\textendash}Disability Index improvement.Conclusion. ETN with and without MTX provided similar benefits in active PsA.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/43/6/1063}, eprint = {https://www.jrheum.org/content/43/6/1063.full.pdf}, journal = {The Journal of Rheumatology} }